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ABSTRACT 
Objective: Indonesia has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), with 6800 new cases of MDR-TB annually and a 
previously reported cure rate of 51%. This study aimed to identify the risk factors that affect the development of MDR-TB in the diverse population 
of West Papua. 
Methods: A case–control study was conducted in Sorong Regency Regional Hospital, a referral center for MDR-TB in West Papua. Data were 
obtained from medical records of patients with relapsed TB between January 2014 and September 2017. Extracted data included demographic 
characteristics, family history, medication history (type of medication and duration), smoking history, supporting examinations (sputum test for 
acid-fast bacilli [AFB] and radiologist interpretation of thoracic X-ray), and comorbidities (HIV and diabetes mellitus). 
Results: Among 549 patients with suspected MDR-TB, 45 were confirmed to have MDR-TB. These 45 patients were defined as the case group and 
compared with a control group of 45 relapsed patients who had drug-sensitive TB. A great number of subjects in both case and control groups 
(44.4% and 57.8%) were categorized as previously lost to follow-up. Bivariate analysis using the chi-squared test found that an AFB result of+3 
(odds ratio [OR]: 5.33, 95% confidence interval [CI] 1.76–16.09), diabetes mellitus (OR: 6.14, 95% CI 1.26–29.89), and completion of intensive-
phase category I anti-TB therapy (OR: 3.25, 95% CI 1.04–10.07) were associated with MDR-TB. 
Conclusion: These clinical variables provide initial information about MDR-TB in West Papua and will assist clinicians to manage patients in related 
populations who have these risk factors. 
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INTRODUCTION 
The magnitude of the global problem of tuberculosis (TB) disease is 
relatively high but differs around the world. TB is regarded as one of 
the top 10 leading causes of death worldwide and the leading cause 
of death from a single infectious disease. According to the latest 
World Health Organization (WHO) global report in 2017, 10.4 
million people were estimated to be ill from TB, with an estimated 
1.3 million deaths among HIV-negative TB patients and an additional 
374,000 deaths among HIV-positive TB patients. Most cases in 2016 
occurred in Asia, with 56% of total cases estimated to occur in India, 
Indonesia, China, Philippines, and Pakistan [1]. 
The development of drug-resistant TB during treatment remains the 
main problem. Global WHO surveillance in 2017 reported 490,000 
cases of multidrug-resistant TB (MDR-TB) and 110,000 cases of 
rifampicin-resistant TB (RR-TB) in 2016. From another perspective, 
cases of MDR-TB represent 4.1% of newly diagnosed cases and 19% 
of cases of relapsed previously treated TB [1-4]. 
According to WHO, Indonesia is included in the top 30 countries 
with high TB/TB-HIV/MDR-TB burden. Indonesia itself has an 
estimated 6,800 new cases of MDR-TB every year, which comprise 
2.8% of new cases and 16% of previously treated cases. Managing 
MDR-TB in Indonesia remains a challenge: surveillance data from 
2015 showed that the rate of successful treatment of MDR-TB was 
only 51% [1-3]. In addition to its relatively low cure rate, MDR-TB 
treatment requires regular monitoring of the patient’s compliance 
and multiple adverse drug reactions. These factors account for the 
high cost of MDR-TB management. 
Demographically, Indonesia is comprised of a dense population with 
rich ethnicities and various culture/tradition-influenced lifestyles. 
West Papua, a province in the east of Indonesia, has a diverse 
population that consists of indigenous Papuans and local 
immigrants. In addition to the mixed ethnicity of West Papua, the 
region has inadequate health care facilities because it is a distant 
rural area with underdeveloped infrastructure. These conditions, 
combined with limited health surveillance data and multiple disease 
burdens including epidemic TB, mean that treating TB/MDR-TB/TB-
HIV patients in daily clinical practice is a complex challenge. 
The development of drug-resistant TB occurs because of 
spontaneous mutations among susceptible bacilli; it can be both 
primary and acquired. Several key risk factors have been identified 
in patients with MDR-TB, including demographic factors, smoking 
habits, comorbidities such as HIV and diabetes mellitus (DM), 
compliance with drug treatment, previous treatment category, 
strength of positivity of sputum AFB smear, chest radiographic 
findings, and evidence of extrapulmonary tuberculosis.[5] Two case–
control studies by Barroso et al. [6] (2003) and Rifat et al. [7] (2014) 
found that current smoking and a past history of smoking are risk 
factors for the development of MDR-TB. 
Chuchottaworn et al. [8] (2015) reported that being HIV positive 
was not a risk factor for MDR-TB, although Swaminathan et al. [9] 
(2005) showed that the proportion of TB drug resistance was higher 
among HIV-positive patients. These inconsistent findings prompted 
the investigation of whether being HIV positive is a risk factor, 
because of the high prevalence of HIV in Indonesia. A recent meta-
analysis by Liu et al. [10] (2017) involving 9289 individuals showed 
that there was a significant association between DM and MDR-TB. 
Several studies have also shown that other risk factors including 
treatment failure or discontinuation, sputum AFB smear score+3, 
and having pleural effusion/cavitation are significantly associated 
with MDR-TB [8, 11]. 
This case–control study aimed to identify the characteristics of 
patients and risk factors associated with the development of MDR-
TB among patients with relapsed TB in West Papua province, 
Indonesia. The data were obtained indirectly from the medical 
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records of patients who had been treated at one of the government 
hospitals responsible for MDR-TB referral and treatment. The 
results of this study are expected to provide insight into MDR-TB in 
West Papua and enhance health prevention and management of 
MDR-TB in the diverse population of Indonesia. 
MATERIALs AND METHODS 
This study was conducted in a referral center of West Papua 
province, Indonesia, as a retrospective case–control study with age-
and sex-matched controls and patients with suspected pulmonary 
MDR-TB. Data were obtained indirectly from the medical records of 
patients enrolled between January 2014 and September 2017 at 
Sorong Regency Regional General Hospital in West Papua. A total of 
549 patients suspected to have MDR-TB who registered at the 
directly observed treatment, short course (DOTS) clinic were 
included. Inclusion criteria were: (1) ≥17 y old, (2) a history of 
consumption of anti-TB drugs, (2) Mycobacterium tuberculosis 
detected by GeneXpert (Xpert MTB/RIFassay) and the Ziehl–Neelsen 
(acid fast staining) method, and (3) complete data on the TB 
database. An exclusion criterion was unavailable data for the 




Fig. 1: Scheme of data collection 
Abbreviation: MDR-TB: multidrug-resistant tuberculosis 
 
Of the patients registered, 48 were diagnosed with MDR-TB; three of 
these patients were excluded because they had primary drug-
resistant TB or incomplete data about previous TB medications. The 
selection of matched controls was randomized among patients with 
non-MDR TB; the age and sex of MDR-TB subjects were matched 
with those of 501 non-MDR TB patients who fit the inclusion 
criteria. Age differences were classified as ±3 y. Data were usually 
acquired from the basic information questionnaire about TB that 
was completed by the general practitioner and the internal medicine 
specialist in charge of the DOTS clinic. The patients were 
anonymized and collection of the data was approved by the hospital 
authorities or the committee in charge of prevention and 
management of TB in the hospital. 
Data obtained from the participants included demographic 
characteristics (age, sex, family members with TB under the same 
roof), and smoking history as lifestyle behavior. The medication 
history that was obtained from these patients was classified into 
several categories (lost to follow-up, failure of treatment, completed 
treatment without follow-up, and relapse), and the number of months 
patients consumed TB medications was further classified by whether 
they completed the 2-month intensive phase of treatment. Patients 
who underwent non-first-line regimens of TB medication or second-
category treatment were also documented. Supporting examinations 
such as evidence of extrapulmonary TB, pretreatment AFB sputum 
smear (strength of positivity), and comorbidities (HIV/AIDS and DM) 
were documented. The radiology information was the radiologist’s 
interpretation of a plain chest radiograph, the results of which were 
categorized as presence or absence of infiltrate in the lung field, and 
the presence of cavitation, pneumothorax, fibrosis, atelectasis, or 
pleural effusion. TB diagnosis in this study was based on AFB staining 
of a sputum smear using the Ziehl–Neelsen method and culture 
resistance was assessed using GeneXpert. 
Demographic and clinical data from the participants were analyzed 
using IBM Corp. released 2012 IBM SPSS Statistics for windows 
version 21, Armony NY: IBM Group. Descriptive analysis compared 
the two groups: MDR-TB subjects (case group) vs non-MDR-TB 
subjects (control group). Further analysis of variables included in 
this study was performed using the chi-squared test while 
variable(s) that could not be analyzed with this test were evaluated 
using Fisher’s exact test. 
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RESULTS 
This study included 90 participants: 45 patients with MDR-TB (the 
case group) and 45 patients with non-MDR TB (the control group). 
The participants in each group were predominantly men (66.7%) 
(30 vs 15). The age of the study population ranged from 17 to 78 y 
with a median of 38 and 40 y for the case and control groups, 
respectively (table 1). 
 
Table 1: Characteristics of subjects 
Characteristics of the sample MDR-TB N (%) Non-MDR-TB N (%) 
Gender   
Male 30 (66.6) 30 (66.6) 
Female 15 (33.4) 15 (33.4) 
Age   
Median 38 40 
Min 18 17 
Max 76 78 
Family history of tuberculosis   
Yes 9 (20) 0 (0) 
No 36 (80) 45 (100) 
Extrapulmonary tuberculosis   
Yes 1 (2.2) 0 
No 44 (97.8) 45 (100) 
Categories of medication history   
Patients lost to follow-up 20 (44.4) 26 (57.8) 
Failed to convert 7 (15.6) 6 (13.3) 
Complete 4 (8.9) 7 (15.6) 
Relapse 14 (31.1) 6 (13.3) 
 
Documentation of the social background showed that none of the 
control group shared a house with a family member with TB or had 
a confirmed diagnosis of extrapulmonary TB. In contrast, nine 
subjects from the case group (20%) had family who had been 
diagnosed with TB and one subject (1.1%) had extrapulmonary TB 
(table 1). 
Comparison of the history of consumption of anti-TB drugs for 
evaluation of the compliance of the subject population in both 
groups showed corresponding numbers in each category. Both case 
and control groups were dominated by subjects that fell within the 
default/discontinue category: 44.4% and 57.8%, respectively. 
However, there was a marked distinction in the category of relapse: 
31.1% in the case group vs 13.3% in the control group (table 1). 
 
Table 2: Medication history (Category I) of subjects 
Duration of Category I medication (months) MDR-TB N (%) Non-MDR-TB N (%) 
1 1 (2.2) 6 (13.3) 
2 4 (8.9) 7 (15.6) 
3 10 (22.2) 11 (24.4) 
4 4 (8.9) 2 (4.4) 
5 3 (6.7) 2 (4.4) 
6 20 (44.4) 16 (35.6) 
7 1 (2.2) 0 
9 1 (2.2) 1 (2,2) 
12 1 (2.2) 0 
 
Table 2 shows the number of months of first-line anti-TB drug 
consumption in the case and control groups. Further documentation 
showed a lack of compliance in reaching the third month of 
consumption: 33.3% in the case group and 53.3% in the control 
group. However, a significant number of subjects in both the case 
and control groups (44.4% and 35.6%, respectively) reached their 
sixth month of therapy, and there were several subjects who 
consumed anti-TB medication for more than six months (6.6% in the 
case group and 2.2% in the control group). 
A comparison of the risk factors between the case and control 
groups included smoking habits, chest radiographic appearance, 
status and duration of previous TB treatment, comorbidities (HIV 
and DM), category of previous anti-TB drug consumption, and 
sputum culture results. 
The proportion of smokers in both groups was similar. Patients who 
were current or past regular smokers comprised 53.3% of the case 
group and 55.6% of the control group. Statistical analysis found no 
significant association of this factor with MDR-TB vs non-MDR-TB (P = 
0.399). 
All patients included in this study were tested for HIV. The 
proportion of HIV-positive patients was higher in the case group 
than in the control group (6 [13.3%] vs 2 [4.4%] patients), but this 
difference was not significant. Similar results were found for chest 
radiographic interpretations and history of non-first-line TB 
treatment. The case group had a higher number of subjects with 
noninfiltrated or typical radiological images compared with the 
control group (7 [15.6%] vs 3 [6.7%]; P = 0.180). 
However, variable chest radiograph interpretations were found in 
the case group (table 3): three patients had lung cavitation, three 
had atelectasis, and one patient had a fibrotic lung. Statistical 
analysis of the history of non-first-line TB treatment in both groups 
showed no significant difference, despite a higher proportion in the 
case group compared with the control group (11 [24.4%] vs 6 
[13.3%] subjects, respectively; P = 0.178). In contrast, in the control 
group, a greater number of subjects had failed or defaulted previous 
TB treatment compared with the case group (32 [71.1%] vs 27 
[60%] subjects; P = 0.267) (table 4). 
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Table 3: Bivariate analysis of variables 
Variables MDR-TB N (%) Non-MDR TB N (%) P-value OR (95% CI) 
Smoking status     
Yes 21 (53.3) 25 (55.6) 0.399 0.71 (0.3–1.6) 
No 24 (46.7) 20 (44.4)   
HIV      
Positive  6 (13.3) 2 (4.4) 0.138 3.3 (0.63–17.36) 
Negative 39 (86.7) 43 (95.6)   
Diabetes mellitus     
Yes 10 (22.2) 2 (4.4) 0.013* 6.14 (1.26–29.89) 
No 35 (77.8) 43 (95.6)   
Thoracic X-ray     
Infiltrate 38 (84.4) 42 (93.3) 0.180 2.579 (0.62–10.69) 
No infiltrate 7 (15.6) 3 (6.7)   
AFB sputum smear     
+3 18 (40) 5 (11.1) 0.002* 5.33 (1.76–16.09) 
<+3  27 (60) 40 (88.9)   
Duration of category I     
Completed intensive phase 40 (88.9) 32 (71.1) 0.035* 3.25 (1.04–10.07) 
Not completed intensive phase 5 (11.1) 13 (28.9)   
Treatment status     
Default or failure 27 (60) 32 (71.11) 0.267 0.609 (0.253–1.466) 
Other 18 (40) 13 (28,89)   
Category II treatment     
Yes 11 (24.4) 6 (13.33) 0.178 2.103 (0.703–6.292) 
Non-category II 34 (75.56) 39 (86.67)   
*P<0.05 
 
Table 1: Chest radiograph appearance 
 MDR-TB Non-MDR-TB 
Thoracic X-ray appearance 3 cavities 
3 atelectasis 
1 fibrotic lung 
2 pleural effusion 
1 pneumothorax 
 
DM was identified in 10 patients (22.2%) in the case group and two 
patients (4.4%) in the control group. Further statistical analysis found 
a significant association of this risk factor with the development of 
MDR-TB (OR: 6.14, 95% CI 1.26–29.89; P = 0.013). In the case group, 
significantly more patients had completed the intensive phase of first-
line anti-TB treatment (2 mo) compared with the control group (40 
[88.9%] vs 32 [71.1%]; OR: 3.25, 95% CI 1.04–10.07; P = 0.035). 
Staining for AFB in sputum of patients included in this study found 
that 18 (40%) in the case group vs only five (11.1%) in the control 
group had a result of+3. Further analysis found that an AFB score of+3 
was significantly associated with MDR-TB compared with a score of 
less than+3 (OR: 5.33, 95% CI 1.76–16.09; P = 0.002). 
DISCUSSION 
This study provides the first description of TB patients, especially those 
with MDR-TB, in the region of West Papua, Indonesia. Regarding the 
prevalence of MDR-TB in the region, we report the first data confirming 
the occurrence of drug resistance among patients with relapsed TB. The 
study was conducted among relapsed patients because of previous 
evidence showing that patients with a history of TB treatment have an 
estimated 10 times higher risk of developing MDR-TB. 
In our study, most patients with MDR-TB were male (66.6%), and a 
family history of tuberculosis was only identified in 20% of the case 
group. This gender proportion was similar to that in studies by 
Magee et al.[5] and Chuchottaworn et al.[8], where men dominated 
the patients with MDR. The present study did not analyze gender as 
a risk factor, although Faustini et al.[12] hypothesized that factors 
such as compliance might have played a role in this phenomenon. 
Although contact with TB patients has often been reported as a risk 
factor for primary TB, there is limited information about the family 
history of TB for patients with MDR-TB. The number of cases in the 
present study is similar to that in Casal et al.[13] and Raazi et al.,[14] 
who found that respectively 22.5% and 20.37% of patients with 
MDR-TB had a family history of TB. However, neither of these 
studies found a significant association of this variable with MDR-TB. 
Among the relapsed patients who were included in the present 
study, the majority of both groups fell within the category of lost to 
follow-up after previous treatment. Further analysis comparing the 
medication status of category I treatment found that it was not a 
significant risk factor for the development of MDR-TB, although 
completing the intensive phase (2 mo) of category I treatment was 
found to be associated with the occurrence of MDR-TB. Analysis of 
these data should be critically addressed. A study by Hirpa et al. 
found similar results, in that patients who underwent 2–7 mo of 
treatment were classified as at risk of MDR-TB.[15] Cox et al. studied 
the biomolecular changes that amplify resistance and found these to 
be highest during the intensive phase of treatment when patients 
were taking the most drugs and/or were hospitalized. This study 
also suggested the possibility that patients were infected with 
multiple strains of TB, and after anti-TB drugs were administered, 
the resistant strain remained whereas drug-susceptible strains were 
diminished.[16] Another factor that should be considered when 
addressing this finding is the low compliance among TB patients in 
the maintenance phase of treatment, as reported by 
Castelnuovo.[17] However, the end result of category I treatment is 
not consistent with previous evidence reported by Stosic et al., 
namely that treatment default and loss to follow-up are risk factors 
for MDR-TB.[18] 
In the present study, comorbidities such as HIV and DM were found 
to be more prevalent in the case group compared with the control 
group, but statistical analysis of these comorbidities found that only 
DM was significant. A meta-analysis including 9289 patients from a 
number of studies found that DM increased the risk of TB (pooled 
statistic OR: 1.71, 95% CI 1.32–2.22).[10] This finding is supported 
by previous study who reported that DM patients with TB usually 
had higher mycobacterial loads and therefore a higher possibility of 
bacillary mutation and the occurrence of MDR. They also noted that 
patients with DM had impaired immune responses marked by 
decreased production of immune components such as interferon-γ. 
In addition, Pasipanodya et al. found that patients with DM had 53% 
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lower plasma levels of rifampicin.[19] Despite the lack of 
significance of the association of HIV and MDR-TB in the present 
study, the results show a trend toward association compared with 
drug-sensitive TB, which is consistent with previous reports. 
Our study showed that patients who had a positive sputum AFB 
smear score of+3 had a higher risk of developing MDR-TB. This 
finding accords with that of Chuchottaworn et al., who also 
demonstrated an association of sputum AFB smear score+3 with 
MDR-TB (OR: 13.09, 95% CI 4.64−36.91).[8] Caetano Mota et al.[20] 
found that patients with a sputum AFB smear score of+3 had an 11.7 
times higher risk of delayed sputum conversion because of the high 
bacterial density in sputum. This might affect the development of 
drug-resistant strains of TB during treatment. Djouma et al. also 
reported that a pretreatment sputum AFB score of+3 was associated 
with a higher rate of treatment failure and delayed sputum 
conversion [21]. 
In contrast to other studies, our study found that smoking history 
was not a risk factor for developing MDR-TB. This finding is 
probably because of the prevalence of smoking in both case and 
control groups: over 50% of the relapsed patients had a history of 
smoking. This result should be acknowledged because it has been 
shown that smoking is one of the determinants of TB, and might be 
the predictor of a delayed response to anti-TB drugs [5]. 
The results of interpretation of the chest radiographs showed that 
MDR-TB (case group) patients had a slightly different appearance 
compared with those with non-MDR TB (control group). Variant 
chest radiographic findings including lung cavitation, atelectasis, and 
fibrotic lung were identified in the case group. Although the 
differences between groups were not statistically significant, they 
might affect the prognosis and morbidity of the patients. Two 
studies have reported the presence of lung cavitation as a risk factor 
for MDR-TB [6, 11]. Although the literature concerning the 
relationship between lung cavitation and MDR-TB is scarce, it could 
be hypothesized that the conditions inside the cavitations (high level 
of oxygenation and protection by the cavity wall) could prevent the 
anti-TB drugs reaching adequate inhibitory concentrations. 
This study was conducted in a rural area of Indonesia where health 
education, including that about communicable diseases like TB and 
HIV, is limited. This study faced several limitations in the collection 
of data because registration and data availability are not fully 
computerized and recorded. The present study also had a limited 
sample size for several reasons: for instance, there were a number of 
subjects who resided in more distant areas where limited access to 
transportation might create obstacles to health access. Thus, limited 
data were available for these subjects. 
However, the present study provides the first view of MDR-TB 
patients in West Papua province, where Sorong Regency Regional 
Hospital has become the referral center for MDR-TB patients. In 
addition to the geographical obstacles that the region faces, it has 
limited numbers of health centers that can provide treatment for TB 
patients, especially those with MDR-TB. 
CONCLUSION 
This study identified a number of relapsed patients who were 
diagnosed with MDR-TB. Statistical analysis of this population 
identified some alarming information; for instance, only the MDR-TB 
case group contained patients who had extrapulmonary TB or a 
family history of TB, and it contained a larger proportion of patients 
with HIV. Further analysis showed that DM, previous completion of 
2 mo of intensive TB treatment, and a score of+3 for sputum AFB 
were associated with MDR-TB. 
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